Generic

May 14, 2019

Price fixing case caps a terrible week for generics

Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.

Price fixing case caps a terrible week for generics

Civica Rx goes where generics companies fear to tread

Pfenex readies to swim upstream with Forteo copycat

Biosimilar knockbacks expose increasing big pharma focus

Private equity cleans up Sanofi’s failed generics foray

Interview – Rani’s pill injector promises much, but is still preclinical

Novartis investors put faith in new chief

Teva investors applaud and staff revolt, as Schultz swings the axe

A determined FDA takes down Teva’s blockbuster

Abbvie sets the date for cash cow slaughter

Is parting such sweet Soriot for Astrazeneca?

Latest Reports

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

Editor's Picks

Car-T sales have disappointed, but has the sellside’s outlook shifted enough?

$1bn Corindus deal gets Healthineers off the acquisition blocks

Clovis investors feel more Lynparza pressure

A recap on the past few months of data digging and analysis

Oncology's haves and have-nots